ArticleGeburtshilfe und Frauenheilkunde2025
Congenital Imprinting Diseases: Aetiology, Pre- and Perinatal Manifestations, Diagnosis and Care of Affected Families and Pregnancies.
Article in Geburtshilfe und Frauenheilkunde, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Congenital Imprinting Disorders (ImpDis) are caused by abnormal expression of parentally imprinted genes. They are characterized by disturbances of imprinting marks which are a specific type of epigenetic signatures and occur either sporadic or familial. So far, twelve ImpDis have been identified, eight of them manifest prenatally or in the neonate period. With exception of abdominal wall defects, ImpDis are rarely associated with major malformations, but predominant early manifestations are disturbed pre- and/or postnatal growth, muscular hypotonia, neonatal feeding difficulties and metabolic/hormonal dysfunction. With few exceptions prenatal clinical features of ImpDis are unspecific and manifest only in the late second or third trimester. In some ImpDis, behavioural, developmental, and neurological symptoms might emerge, and in single ImpDis there is a higher risk of cancer in childhood. Prenatal diagnosis plays a crucial role in appropriate pregnancy management and initial care of the newborn, which in turn has positive impact on the life-long outcome of the patient. Furthermore, the diagnosis of ImpDis is relevant for the prevention of pregnancy risks such as preeclampsia and possible reproductive problems in future pregnancies and other family members. Genetic analysis is not straightforward, and imprinting disturbances may escape both DNA sequencing analysis and (molecular-)cytogenetic diagnostics. After introducing the topic with a case report, this review focuses on the recognition of ImpDis including maternal and family history, exogeneous and genetic risk factors, fetal imaging, and genetic findings as well as interdisciplinary care and treatment approaches in the management and decision making of affected families and pregnancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.